These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 27266545

  • 1. Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer.
    Lu S, Zhang J, Ye M, Wang B, Wu B.
    Pharmacogenomics; 2016 Jun; 17(9):985-94. PubMed ID: 27266545
    [Abstract] [Full Text] [Related]

  • 2. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Morgan P, Woolacott N, Biswas M, Mebrahtu T, Harden M, Hodgson R.
    Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
    [Abstract] [Full Text] [Related]

  • 3. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
    Lee JA, Bubendorf L, Stahel R, Peters S.
    Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China.
    Lu S, Yu Y, Fu S, Ren H.
    PLoS One; 2018 May; 13(10):e0205827. PubMed ID: 30352060
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
    Zhou ZY, Mutebi A, Han S, Bensimon AG, Louise Ricculli M, Xie J, Dalal A, Culver K.
    J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Crizotinib and testing for ALK.
    Shaw AT, Solomon B, Kenudson MM.
    J Natl Compr Canc Netw; 2011 Dec; 9(12):1335-41. PubMed ID: 22157554
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
    Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J.
    Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
    [Abstract] [Full Text] [Related]

  • 10. Treatment and detection of ALK-rearranged NSCLC.
    Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R.
    Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
    [Abstract] [Full Text] [Related]

  • 11. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
    Guo L, Zhang H, Shao W, Chen B.
    Drug Des Devel Ther; 2015 Aug; 9():5491-7. PubMed ID: 26491259
    [Abstract] [Full Text] [Related]

  • 12. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
    Yi ES, Chung JH, Kulig K, Kerr KM.
    Mol Diagn Ther; 2012 Jun 01; 16(3):143-50. PubMed ID: 22506598
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.
    Oncologist; 2016 Jun 01; 21(6):762-70. PubMed ID: 27245569
    [Abstract] [Full Text] [Related]

  • 15. [ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].
    Audigier-Valette C, Girard N, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlesi F.
    Bull Cancer; 2014 Sep 01; 101(9):823-31. PubMed ID: 25299566
    [Abstract] [Full Text] [Related]

  • 16. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
    Cameron L, Solomon B.
    Drugs; 2015 Jul 01; 75(10):1059-70. PubMed ID: 26076736
    [Abstract] [Full Text] [Related]

  • 17. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M, De Marinis F, Hirsch FR, Gridelli C.
    Int J Oncol; 2014 Aug 01; 45(2):509-15. PubMed ID: 24859689
    [Abstract] [Full Text] [Related]

  • 18. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
    Giroux Leprieur E, Wislez M.
    Bull Cancer; 2016 Feb 01; 103(2):125-6. PubMed ID: 26822904
    [No Abstract] [Full Text] [Related]

  • 19. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.
    Eur J Cancer; 2012 May 01; 48(7):961-73. PubMed ID: 22397764
    [Abstract] [Full Text] [Related]

  • 20. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.
    Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, Zhou C, Camidge DR.
    J Thorac Oncol; 2014 Mar 01; 9(3):e21-3. PubMed ID: 24518095
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.